Blood flow devices in medical research and clinical testing in humans: Are we approaching personalized medicine?

Future Cardiology

Volumn 3, Issue 1, 2007, Pages 71-90

  Sakariassen, Kjell S ^a  

^a KellSa sas   (Italy)

Author keywords

Aspirin; Clopidogrel; Coagulation; Coumarin; Diagnostics; Flow devices; Hemostasis; Heparin; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; COUMARIN; DIPYRIDAMOLE; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; VON WILLEBRAND FACTOR;

BIOMEDICAL TECHNOLOGY ASSESSMENT; BLEEDING; BLOOD FLOW; DIAGNOSTIC PROCEDURE; HUMAN; INDIVIDUALIZATION; MATERIALS TESTING; MEDICAL RESEARCH; NONHUMAN; PERFUSION; PREDICTION; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VALIDATION PROCESS;

EID: 33846502073     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.3.1.71     Document Type: Review

References (93)

1. Baumgartner HR, Haudenschild C: Adhesion of platelets to subendothelium. In: Platelets and theier Role in Hemostasis (Volume 201). Spaet TH (Ed.). New York Academy of Sciences, NY, USA 22-36 (1972).
2. Baumgartner HR: The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc. Res. 5(2), 167-179 (1973).
3. Sakariassen KS, Aarts PA, de Groot PG, Houdijk WP, Sixma J: A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J. Lab. Clin. Med. 102(4), 522-535 (1983).
4. Sakariassen KS, Joss R, Muggli R, Tschopp TB, Sage H, Baumgartner HR: Collagen type III induced ex vivo thrombogenesis in humans: role of platelets and leukocytes in deposition of fibrin. Arterioclerosis 19(2), 276-284 (1990).
5. Hanson SR, Harker LA, Ratner BD, Hoffman AS: In vivo evaluation of artificial surfaces using a nonhuman primate model of arterial thrombosis. J. Lab. Clin. Med. 95(2), 289-304 (1980).
6. Badimon L, Turitto VT, Galvez A, Badimon JJ, Fuster V: Characterization of a tubular flow chamber for studying platelet interaction with biological and prosthetic materials: deposition of indium 111-labelled platelets on collagen subendothelium and expanded polytetrafluorethylene. J. Lab. Clin. Med. 110(6), 706-712 (1987).
7. Badimon L, Badimon JJ, Lassila RR, Heras M, Chesebro JH, Fuster V: Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin and calcium chelation. Blood 78(2), 423-434 (1991).
8. Baumgartner HR: Effects of anticoagulation on the interaction of human platelets with subendothelium in flowing blood. Schweiz. Med. Wochenschr. 106(40), 1367-1368 (1976).
9. Sakariassen KS, Muggli R, Baumgartner HR: Measurements of platelet interaction with components of the vessel wall in flowing blood. In: Methods in Enzymology (Volume 169). Hawiger J (Ed.). New York Academic Press Inc., NY, USA 33-70 (1989).
10. Sakariassen KS, Kuhn H, Muggli R, Baumgartner HR: Growth and stability of thrombi in flowing blood: assessment of platelet surface interactions with computer-assisted morphometry. Thromb. Haemost. 60(3), 392-398 (1988).
11. Sakariassen KS, Hanson SR, Cadroy Y: Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb. Res. 104(3), 149-174 (2001).
12. Barstad RM, Roald HE, Cui W, Turitto VT, Sakariassen KS: A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native blood at the apex of well-defined stenoses. Arterioscler. Thromb. 14(12), 1984-1991 (1994).
13. Ørvim U, Barstad RM, Vlasuk GP, Sakariassen KS: Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear dependent thrombus formation. Arterioscler. Thromb. Vasc. Biol. 15(12), 2188-2194 (1995).
14. Diquelou A, Dupouy D, Cariou R, Sakariassen KS, Boneu B, Cadroy Y: A comparative study of the anticoagulant and antithrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis. Thromb. Haemost. 74(5), 1286-1292 (1995).
15. Ørvim U, Barstad RM, Stormorken H, Brosstad F, Sakariassen KS: Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood. Br. J. Haematol. 95(2), 389-398 (1996).
16. Bossavy JP, Sakariassen KS, Barret A, Boneu B, Cadroy Y: A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb. Haemost. 79(1), 162-168 (1998).
17. Hanson SR, Sakariassen KS: Blood flow and antithrombotic drug effects. Am. Heart. J. 135(5 Pt Suppl. 2), S132-S145 (1998).
18. Kirchhofer D, Sakariassen KS, Clozel M et al.: Relationship between tissue factor expression, deposition of fibrin, platelets and leukocytes on cultured endothelial cells under venous blood flow conditions. Blood 81(8), 2050-2058 (1993).
19. Aznar-Salatti J, Anton P, Nemerson Y, Sakariassen KS: Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide Arg-Gly-Asp-Val. Experiments with flowing non-anticoagulated blood. Blood Coag. Fibrinol. 4(6), 881-890 (1993).
20. Roald HE, Barstad RM, Engen A, Kierulf P, Skjørten F, Sakariassen KS: HN-11500 - a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb. Haemost. 71(1), 103-109 (1994).
21. van Heerde WL, Sakariassen KS, Hemker HC, Sixma JJ, Reutelingsberger CP, de Groot PG: Annexin V inhibits the procoagulant activity of TNF-stimulated endothelial cells under flow conditions. Arterioscler. Thromb. 14(5), 824-830 (1994).
22. Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen KS: Tissue factor pathway inhibitor prevents fibrin deposition on procoagulant subendothelial matrix when exposed to flowing non-anticoagulated human blood. Blood Coag. Fibrinol. 5(5), 755-760 (1994).
23. Barstad RM, Hamers MJ, Stephens RW, Sakariassen KS: Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa dependent thrombus formation. Blood 86(1), 212-218 (1995).
24. Ørvim U, Barstad RM, Örning L et al.: Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood. Arterioscler. Thromb. Vasc. Biol. 17(11), 3049-3056 (1997).
25. Örning L, Hu C-K, Agner E et al.: A cyclic pentapeptide derived from the EGF-2 domain of factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation. Thromb. Haemost. 87(1), 13-21 (2002).
26. Barstad RM, Ørvim U, Hamers MJ, Tjønnfjord G, Brosstad FR, Sakariassen KS: Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb. Haemost. 75(5), 827-832 (1996).
27. Bossavy JP, Thalamas C, Sagnard L et al.: A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 92(5), 1518-1525 (1998).
28. Roald HE, Barstad RM, Kierulf P et al.: Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in human non-anticoagulated blood independently of the blood flow conditions. Thromb. Haemost. 71(5), 665-672 (1994).
29. Cadroy Y, Thalamas C, Sakariassen KS, Boneu B: Superior efficacy of clopidogrel plus acetylsalicyclic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombosis in healthy volunteers. Thromb. Res. 116(4), 293-300 (2005).
30. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen KS, Boneu B: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 101(24), 2823-2828 (2000).
31. Bossavy JP, Cadroy Y, Sakariassen KS, Boneu B, Barret A: Nonfractionated heparin fails to inhibit arterial thrombosis in a human ex vivo thrombosis model. Ann. Vasc. Surg. 13(4), 393-401 (1999).
32. Bossavy JP, Sakariassen KS, Rubsamen K, Thalamas C, Boneu B, Cadroy Y: Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 19(5), 1348-1353 (1999).
33. Bossavy JP, Sakariassen KS, Thalamas C, Boneu B, Cadroy Y: Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis. Effect of anticoagulation level and combination therapy with aspirin. Arterioscler. Thromb. Vasc. Biol. 19(9), 2269-2275 (1999).
34. Andre P, La Rocca T, Delaney SM et al.: Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 108(21), 2697-2703 (2003).
35. Sakariassen KS, Turitto VT, Baumgartner HR: Recollections of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood. J. Thromb. Haemost. 2(10), 1681-1690 (2004).
36. Ørvim U, Roald HE, Stephens RW, Roos N, Sakariassen KS: Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions. Arterioscler. Thromb. 12(12), 1976-1983 (1994).
37. Barstad RM: Impact of disturbed laminar blood flow, fibrillar collagen and tissue factor on thrombus formation. In: Medical Thesis, Nycomed Pharma and Medical Faculty. University of Oslo, Oslo 37-38 (1996).
38. Holme PA, Ørvim U, Hamers MJ et al.: Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with severe stenoses. Arterioscler. Thromb. Vasc. Biol. 17(4), 646-653 (1997).
39. Cadroy Y, Sakariassen KS, Grandjean H, Thalamas C, Boneu B, Sie P: The effect of platelet PIA polymorphism on experimental thrombus formation in man depends on blood flow and thrombogenic surface. Thromb. Haemost. 85(6), 1097-1103 (2001).
40. Cadroy Y, Sakariassen KS, Charlet JP, Thalamas C, Boneu P, Sie P: Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood 98(10), 3159-3161 (2001).
41. Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR: Endothelial cells stimulated with tumor necrosis factor-α express varying amounts of tissue factor resulting in inhomogeneous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J. Clin. Invest. 93(5), 2073-2083 (1994).
42. Sixma JJ, de Groot PG, van Zanten H, Ijsseldijk M: A new perfusion chamber to detect platelet adhesion using a small volume of blood. Thromb. Res. 92(6 Suppl. 2), S43-S46 (1998).
43. Phillips DR, Conley PB, Sinha U, Andre P: Therapeutic approaches in arterial thrombosis. J. Thromb. Haemost. 3(8), 1577-1589 (2005).
44. Sakariassen KS, Cattaneo M, van der Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ: DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 64(1), 224-236 (1984).
45. Fressinaud E, Sakariassen KS, Rothschild C, Baumgartner HR, Meyer D: Shear-rate dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and Hemophilia A. Blood 80(4), 988-994 (1992).
46. Tschopp TB, Weiss HJ, Baumgartner HR: Decreased platelet adhesion of platelets to subendothelium in von Willebrand's disease. J. Lab. Clin. Med. 83(3), 296-300 (1974).
47. Weiss HJ, Turitto VT, Baumgartner HR: Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulter syndrome. J. Lab. Clin. Med. 92(5), 750-764 (1978).
48. Sakariassen KS, Nievelstein PF, Coller B, Sixma JJ: The role of platelet membrane glycoprotein Ib and IIb/IIIa in platelet adherence to artery subendothelium. Br. J. Haematol. 63(4), 681-691 (1986).
49. Weiss HJ, Turitto VT, Baumgartner HR: Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules. Blood 67(2), 322-330 (1986).
50. Weiss HJ, Turitto VT, Baumgartner HR: Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. J. Clin. Invest. 78(4), 1072-1082 (1986).
51. Niuwenhuis HK, Sakariassen KS, Houdijk WPM, Nievelstein PF, Sixma JJ: Deficiency of platelet membrane glycoprotein Iα is associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 68(3), 692-695 (1986).
52. Diaz-Ricart M, Tandon NN, Carretero M, Ordinas A, Bastida E, Jamieson GA: Platelets lacking functional CD36 (glycoprotein IV) show reduced adhesion to collagen in flowing whole blood. Blood 82(2), 491-496 (1993).
53. Joutsi-Korhonen L, Smethurst PA, Rankin A et al.: The low-frequency allele of the platelet collagen signalling receptor glycoprotein VI is associated with reduced functional responses and expression. Blood 101(11), 4372-4379 (2003).
54. Stormorken H, Holmsen H, Sund R et al.: Studies on the haemostatic defect in a complicated syndrome - an inverse Scott syndrome platelet membrane abnormality. Thromb. Haemost. 74(5), 1244-1251 (1995).
55. Barstad RM, Stormorken H, Orning L et al.: Reduced thrombus formation in native blood of homozygous factor VII deficient patients at high arterial wall shear rate. Blood 84(10), 3371-3377 (1994).
56. Weiss HJ, Turitto VT, Vicic WJ, Baumgartner HR: Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency. Blood 63(5), 1004-1014 (1984).
57. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T: Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J. Clin. Invest. 83(1), 288-297 (1989).
58. Remijn JA, Wu YP, Ijsseldijk MJ, Zwaginga JJ, Sixma JJ, de Groot PG: Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions. Thromb. Haemost. 85(4), 736-742 (2001).
59. Cadroy Y, Diquelou A, Dupouy D et al.: The thrombomodulin/protein C/ protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium. Arterioscler. Thromb. Vasc. Biol. 17(3), 520-527 (1997).
60. Cadroy Y, Lemozy S, Diquelou A et al.: Human type II hyperlipoproteinemia enhances platelet-collagen adhesion in flowing non-anticoagulated blood. Arterioscler. Thromb. 13(11), 1650-1653 (1993).
61. Zwaginga JJ, Ijsseldijk MJ, de Groot PG, de Bos-Kuil RL, Sixma, JJ: Defects in platelet adhesion and aggregate formation in uremic bleeding disorders can be attributed to factors in plasma. Arterioscler. Thromb. 11(3), 733-744, (1991).
62. Zwaginga JJ, Ijsseldijk MJ, de Groot PG et al.: Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb. Haemost. 66(6), 638-647 (1991).
63. Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ: Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J. Clin. Invest. 93(1), 204-211 (1994).
64. Nievelstein PF, Sixma JJ, Ottenhof-Rovers M, Wynne HJ, de Groot PG, Banga JD: Platelet adhesion and aggregate formation in type 1 diabetes under flow conditions. Diabetes 40(11), 1410-1417 (1991).
65. Ferreira IA, Mocking ALM, Feijge MAH et al.: Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 26(2), 417-422 (2006).
66. Lisman T, Adelmeijer J, de Groot PG, Janssen HLA, Leebeeks FWG: No evidence for an intrinsic platelet defect in patients with liver cirrhosis - studies under flow conditions. J. Thromb. Haemost. 4(9), 2070-2072 (2006).
67. Weiss HJ, Turitto VT, Vicic WJ, Baumgartner HR: Effect of aspirin and dipyridamole on the interaction of human platelets with subendothelium: studies using citrated and native blood. Thromb. Haemost. 45(2), 136-141 (1981).
68. Roald HE, Orvim U, Bakken IJ, Barstad RM, Kierulf P, Sakariassen KS: Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion. Arterioscler. Thromb. 14(4), 617-621 (1994).
69. Inauen W, Bombeli T, Baumgartner HR, Haeberli A, Straub PW: Effects of the oral anticoagulant phenprocoumon on blood coagulation and thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood: role of dose and shear rate. J. Lab. Clin. Med. 118(3), 280-288 (1991).
70. Inauen W, Baumgartner HR, Bombeli T, Haeberli A, Straub PW: Dose- and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing blood. Arteriosclerosis 10(4), 607-615 (1990).
71. Fressinaud E, Girma JP, Sadler JF, Baumgartner HR, Meyer D: Synthetic RGDS-containing peptides of von Willebrand factor inhibit platelet adhesion to collagen. Thromb. Haemost. 64(4), 589-593 (1990).
72. Kirchhofer D, Tschopp TB, Steiner B, Baumgartner HR: Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Blood 86(10), 3815-3822 (1995).
73. Sakariassen KS, Fressinaud E, Girma J-P, Meyer D, Baumgartner HR: Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen. In: Blood in Contact with Natural and Artificial Surfaces (Volume 516). Leonard EF, Turitto VT, Vroman L (Eds). New York Academy of Sciences, NY, USA 52-65 (1987).
74. Kirchhofer D, Tschopp TB, Baumgartner HR: Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler. Thromb. Vasc. Biol. 15(8), 1098-1106 (1995).
75. Barnes CS, Krafft B, Frech M et al.: Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen. Semin. Thromb. Hemost. 27(4), 337-348 (2001).
76. Sixma JJ, Ijsseldijk MJ, Hindriks G et al.: Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. Arterioscler. Thromb. Vasc. Biol. 16(1), 64-71 (1996).
77. Barstad RM, Hamers MJ, Kierulf P, Westvik A-B, Sakariassen KS: Procoagulant human monocytes mediate tissue factor/factor VIIa-dependent platelet thrombus formation when exposed to flowing nonanticoagulated human blood. Arterioscler. Thromb. Vasc. Biol. 15(1), 11-16 (1995).
78. Weiss HJ, Turitto VT. Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood 53(2), 244-250 (1979).
79. Inauen W, Stocker G, Haeberli A, Straub PW: Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood. Contraception 43(5), 435-446 (1991).
80. Barstad RM, Roald HE, Petersen LB, Stokke KT, Kierulf P, Sakariassen KS: Dietary supplement of omega-3 fatty acids has no effect on acute collagen-induced thrombus formation in flowing native blood. Blood. Coag. Fibrinol. 6(5), 374-381 (1995).
81. Barstad RM, Stephens RW, Hamers MJ, Sakariassen KS: Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb. Haemost. 83(2), 334-337 (2000).
82. Sakariassen KS, Barstad RM, Hamers MJ, Stormorken H: Iohexol, platelet activation and thrombosis. I. Iohexol-induced platelet secretion does not affect thrombus formation in native blood. Acta Radiol. 39(4), 349-354 (1998).
83. Sakariassen KS, Buchmann M, Hamers MJ, Stormorken H: Iohexol, platelet activation and thrombosis. II. Iohexol-induced platelet secretion does not affect collagen- or tissue factor-induced thrombus formation in blood anticoagulated with heparin and aspirin. Acta Radiol. 39(4), 355-361 (1998).
84. Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT, Cohen D: Correction by Factor VIII of the impaired platelet adherence to subendothelium in von Willebrand's disease. Blood 51(2), 267-279 (1978).
85. Sakariassen KS, Bolhuis PA, Sixma JJ: Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to subendothelium. Nature 279(5714), 636-638 (1979).
86. Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA: Adhesion of platelets to human artery subendothelium: effect of Factor VIII-von Willebrand factor of various multimeric composition. Blood 63(1), 128-139 (1984).
87. Sakariassen KS, Bolhuis PA, Blomback M, Thorell L, Blomback B, Sixma JJ: Association between bleeding time and platelet adherence to artery subendothelium. Thromb. Haemost. 52(2), 144-147 (1984).
88. Aznar-Salatti J, Escolar G, Arnau M et al.: An intermediate-purity factor VIII concentrate supports platelet adhesion under flow conditions. Haemophilia 3(1), 14-20 (1997).
89. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, de Groot PG: Recombinant Factor VIIa enhances deposition of platelets with congenital or acquired αIIbβ3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-dependent thrombin generation. Blood 101(5), 1864-1870 (2003).
90. Roald HE, Barstad RM, Bakken IJ, Roald B, Lyberg T, Sakariassen KS: Initial interactions of platelets and plasma proteins in flowing non-anticoagulated human blood with the artificial surfaces Dacron and PTFE. Blood Coag. Fibrinol. 5(3), 355-363 (1994).
91. Schneider PA, Kotze HF, Heyns A, Du P, Hanson SR: Thromboembolic potential of synthetic vascular grafts in baboons. J. Vasc. Surg. 10(1), 75-82 (1989).
92. Zwaginga JJ, Nash G, King MR et al.: Biorheology of Subcommittee of the SSC of the ISTH: Flow-based assays for global assessment of hemostasis. Part 1: Biorheological considerations. J. Thromb. Haemost. 4(11), 2486-2487 (2006).
93. Zwaginga JJ, Sakariassen KS, Nash G et al.: Biorheology Subcommittee of the SSC of the ISTH: Flow-based assays for global assessment of hemostasis. Part 2: Current methods and considerations for the future. J. Thromb. Haemost. 4(12), 2716-2717 (2006).